Consun Pharmaceutical Group Ltd. (1681) AI Stock Analysis

• Market Cap: HK$12.20B
• Dividend Yield: 4.28%
• Average Volume (3M): 2.07M
• Price to Earnings (P/E): 11.4
• Beta (1Y): 0.53
• Revenue Growth: 19.05%
• EPS Growth: 13.68%
• Country: HK
• Employees: 3,164
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.64
• Shares Outstanding: 847,993,400
• 10 Day Avg. Volume: 1,547,551
• 30 Day Avg. Volume: 2,071,738
• PEG Ratio: 0.52
• Price to Book (P/B): 1.53
• Price to Sales (P/S): 2.12
• P/FCF Ratio: 6.43
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$25.20
• Price Target Upside: 63.34% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 9.97
• Revenue Forecast (FY): HK$27.08B

• Rating: 72 Outperform
• Price Target: HK$17.00 ▲(10.17% Upside)

Consun Pharmaceutical Group Ltd. exhibits strong financial performance with robust revenue growth and profitability. The stock's valuation is attractive with a reasonable P/E ratio and a solid dividend yield. However, technical indicators suggest weak momentum, which could pose short-term challenges.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective business strategies, supporting long-term financial stability and expansion.

Profitability Margins

High and improving profit margins suggest effective cost management and pricing power, enhancing the company's ability to reinvest in growth.

Balance Sheet Health

A strong balance sheet with reduced leverage enhances financial flexibility and reduces risk, supporting sustainable growth and investment capacity.

Negative Factors

Cash Flow Data Limitations

Incomplete cash flow data hinders a comprehensive understanding of cash generation and utilization, potentially obscuring financial health insights.

High Cash Reserves

Excessive cash reserves may indicate missed opportunities for investment or return enhancement, potentially impacting growth and shareholder value.

Sustainability of High Growth Rate

Rapid growth can be difficult to maintain, potentially leading to volatility in financial performance if not managed with strategic foresight.

Consun Pharmaceutical Group Ltd. Business Overview & Revenue Model

Company Description

Consun Pharmaceutical Group Ltd. (1681) is a leading pharmaceutical company based in China, specializing in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company primarily focuses on traditional Chinese medicine, modern pharmaceuticals, and healthcare products, catering to both domestic and international markets. With a commitment to innovation and quality, Consun aims to enhance health outcomes through its extensive portfolio of medicines and wellness solutions.

How the Company Makes Money

Consun Pharmaceutical Group Ltd. generates revenue through multiple streams, primarily from the sale of its pharmaceutical products, which include both traditional Chinese medicines and modern pharmaceuticals. The company leverages its robust research and development capabilities to create innovative products that meet the evolving needs of patients. Additionally, Consun benefits from strategic partnerships with healthcare institutions and distributors, enhancing its market reach and distribution efficiency. The company also explores opportunities in export markets, contributing to its revenue growth. Furthermore, ongoing investments in production facilities and technology help to optimize costs and improve margins, ultimately driving profitability.

Consun Pharmaceutical Group Ltd. Financial Statement Overview

Summary

Consun Pharmaceutical Group Ltd. demonstrates strong financial health with robust revenue growth and profitability margins. The balance sheet is stable with decreasing leverage and increasing equity. However, limited recent cash flow data restricts a full assessment of cash generation efficiency.

Income Statement

Consun Pharmaceutical Group Ltd. has demonstrated strong growth in revenue, consistently increasing from 2019 to 2024. The company shows impressive profitability with a gross profit margin consistently above 75% and a net profit margin improving from 4.6% in 2019 to 30.7% in 2024. EBIT and EBITDA margins have also shown positive trends, indicating effective cost management. However, the high growth rate may pose sustainability challenges in future periods.

Balance Sheet

The company maintains a robust balance sheet with a strong equity position and increasing total assets. The debt-to-equity ratio has improved, reflecting reduced leverage over the years. The return on equity has also improved significantly, indicating efficient use of equity capital. Nonetheless, high cash reserves might suggest underutilization of funds, which could be optimized for growth or shareholder returns.

Cash Flow

Consun Pharmaceutical Group Ltd. has maintained positive free cash flow consistently, although recent data is unavailable for comprehensive analysis. The company has shown the ability to generate cash from operations, but the lack of recent cash flow data limits a full assessment. Historical trends suggest sound cash flow management, but recent growth in free cash flow percentages are needed for a clearer picture.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.27B	2.97B	2.59B	2.34B	2.04B	1.75B
Gross Profit	2.50B	2.24B	1.92B	1.76B	1.53B	1.32B
EBITDA	1.14B	1.05B	963.06M	785.89M	728.71M	618.79M
Net Income	1.01B	910.46M	784.53M	682.91M	590.17M	498.79M
Balance Sheet
Total Assets	6.09B	5.85B	5.51B	4.89B	4.36B	3.95B
Cash, Cash Equivalents and Short-Term Investments	4.04B	3.87B	3.58B	3.04B	2.43B	1.94B
Total Debt	253.35M	267.17M	511.53M	460.18M	610.97M	549.41M
Total Liabilities	1.45B	1.46B	1.59B	1.45B	1.45B	1.43B
Stockholders Equity	4.35B	4.10B	3.63B	3.15B	2.62B	2.22B
Cash Flow
Free Cash Flow	1.14B	977.99M	766.41M	896.09M	627.29M	818.36M
Operating Cash Flow	1.23B	1.09B	818.97M	947.68M	725.54M	867.06M
Investing Cash Flow	-901.34M	-186.91M	-231.77M	-368.80M	-298.31M	-25.70M
Financing Cash Flow	-652.30M	-729.26M	-280.10M	-342.20M	-166.66M	-279.80M

Consun Pharmaceutical Group Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 15.43
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1681, the sentiment is Negative. The current price of 15.43 is above the 20-day moving average (MA) of 14.82, above the 50-day MA of 15.41, and above the 200-day MA of 12.06, indicating a neutral trend. The MACD of -0.11 indicates Negative momentum. The RSI at 46.06 is Neutral, neither overbought nor oversold. The STOCH value of 55.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1681.

Consun Pharmaceutical Group Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2877	73 Outperform	HK$6.41B	7.19	10.85%	5.95%	-20.64%	-25.39%
1681	72 Outperform	HK$12.20B	11.41	25.92%	4.28%	19.05%	13.68%
0719	70 Outperform	HK$9.95B	11.63	7.48%	4.29%	1.65%	-16.38%
0570	54 Neutral	$11.63B	-40.67	-1.26%	3.36%	-9.58%	-128.83%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
0460	43 Neutral	$12.60B	―	-1.87%	0.82%	19.21%	-115.91%

Consun Pharmaceutical Group Ltd. Corporate Events

Consun Pharmaceutical Schedules EGM for Share Scheme and Governance Amendments

Consun Pharmaceutical Group Ltd. has announced the scheduling of an Extraordinary General Meeting (EGM) on December 23, 2025, to discuss and approve the proposed adoption of a Share Award Scheme and amendments to its memorandum and articles of association. This move is aimed at holding treasury shares and adopting new governance documents, potentially impacting shareholder engagement and corporate governance practices.

Consun Pharmaceutical Proposes New Share Award Scheme

Consun Pharmaceutical Group Ltd. has proposed the adoption of a Share Award Scheme to incentivize and reward participants for the growth and development of the company. This scheme, which requires shareholder approval, aims to grant new shares under the Listing Rules, enhancing the company’s ability to motivate its workforce. The announcement also notes the expiration of the 2013 Share Option Scheme and the introduction of the 2024 Share Option Scheme, which has not yet granted any options but has set limits for future share allocations.

Consun Pharmaceutical Proposes Amendments to Memorandum for Treasury Shares

Consun Pharmaceutical Group Limited, a company incorporated in the Cayman Islands, has announced proposed amendments to its existing memorandum and articles of association. These amendments aim to allow the company to hold and dispose of repurchased shares as treasury shares, in line with Cayman Islands law and recent changes to the Hong Kong Stock Exchange’s listing rules. The changes are pending shareholder approval at an upcoming extraordinary general meeting.

Consun Pharmaceutical Group Redesignates Professor Zhu Quan as Non-Executive Director

Consun Pharmaceutical Group Ltd. announced the redesignation of Professor Zhu Quan from an executive director to a non-executive director, effective September 25, 2025. This change allows Professor Zhu to focus more on other commitments while continuing to contribute to the company’s research and development efforts. The redesignation is part of the company’s ongoing efforts to optimize its leadership structure and maintain its competitive edge in the pharmaceutical industry.

Consun Pharmaceutical Group Announces Board Composition and Committee Roles

Consun Pharmaceutical Group Ltd. has announced the composition of its board of directors and the roles of each member. The board includes executive, non-executive, and independent non-executive directors, and has established four committees: Audit, Remuneration, Nomination, and Environmental, Social and Governance. This announcement provides clarity on the governance structure of the company, potentially impacting its strategic direction and stakeholder engagement.